Moderna, Inc. (MRNA)

Will Moderna Stock Drop to $25? 1 Wall Street Analyst Thinks So.

In the dark days of the coronavirus pandemic, Moderna (MRNA 0.42%) was a ray of light in more ways than one. The healthcare company's innovative Spikevax was one of the go-to vaccines that sped to market, not only protecting hundreds of millions of people from COVID-19, but also producing gobs of revenue and healthy profits.

Moderna: A Generational Opportunity for Investors in 2025

As bad as it may look on the charts, Moderna's NASDAQ: MRNA post-COVID let-down and market reset are over. The company stock trades at rock bottom in early 2025 and presents a generational opportunity in cutting-edge biotech.

Moderna shares move higher as investors look beyond Q4 losses to pipeline potential

Moderna Inc (NASDAQ:MRNA, ETR:0QF) shares added more than 8% during Tuesday's session as investors remained optimistic about the company's long-term strategy following mixed fourth quarter earnings. The company last week reported a wider-than-expected loss for Q4, as revenue surpassed expectations.

Analyst Confident In Moderna's Cancer Vaccine But Highlights Other Challenges

On Friday, Moderna Inc. MRNA reported a fourth-quarter EPS loss of $(2.91), missing the consensus of $(2.62), a turnaround from EPS income of $0.55 a year ago.

A lot of concern around Moderna over next year or so, says Jefferies Michael Yee

Michael Yee, Jefferies senior analyst, joins 'Closing Bell Overtime' to talk Moderna Q4 results.

Movers: Roku, Moderna, GameStop, Palo Alto

Moderna, Inc.: Working Hard But Competition Is Working Harder

MRNA's stock surged 4,211% during COVID-19 but has since plummeted to $31, reflecting a significant bubble and raising concerns about its future. Declining revenue and net income, driven by reduced COVID-19 vaccine demand and RSV market challenges, highlight MRNA's financial instability. MRNA's competitive landscape, particularly against Pfizer, and higher forward P/S ratio suggest the stock is overvalued and faces tough competition.

Moderna Q4 Earnings and Revenues Beat, COVID Vaccine Sales Decline

MRNA's earnings and revenues surpass estimates in the fourth quarter of 2024. The company reiterates 2025 total revenue guidance.

Moderna's Q4 Loss Wider Than Expected

Moderna (MRNA 2.91%), the biotech company known for its Spikevax COVID-19 vaccine, released its fourth-quarter earnings on Feb. 14. The results revealed significant financial challenges as the market for COVID vaccines shifts from government contracts to a seasonal commercial market.

Moderna (MRNA) Reports Q4 Loss, Tops Revenue Estimates

Moderna (MRNA) came out with a quarterly loss of $2.50 per share versus the Zacks Consensus Estimate of a loss of $2.69. This compares to earnings of $0.55 per share a year ago.

Moderna beats on revenue but loses more than expected as it scales down manufacturing

Moderna beat on fourth-quarter revenue but lost more than expected for the period, as the biotech company continues to slash costs and see lower demand for its Covid vaccine. It marks another quarter of growing pains for the company, which is racing to launch new products and recover from the rapid decline of its once-booming Covid business.

Moderna's wider-than-expected loss and soft guidance weigh on battered stock

COVID-19 vaccine sales topped consensus but RSV sales remain modest

Moderna posts bigger loss than expected as vaccine maker scales down manufacturing

Moderna reported a bigger-than-expected quarterly loss on Friday, hit by a charge related to its efforts to scale down manufacturing amid weakening demand for its COVID-19 vaccine.

Moderna Reports Fourth Quarter and Fiscal Year 2024 Financial Results and Provides Business Updates

Reports fourth quarter revenues of $1.0 billion, GAAP net loss of $(1.1) billion and GAAP EPS of $(2.91); loss includes approximately $0.2 billion of non-cash charges related to manufacturing resizing Reports full-year revenues of $3.2 billion, GAAP net loss of $(3.6) billion and GAAP diluted EPS of $(9.28) Expects 2025 revenue range of $1.5 to 2.5 billion andending cash balance of approximately $6 billion Submitted three investigational mRNA products for regulatory approval, including Moderna's next-generation COVID vaccine, RSV vaccine for high-risk adults aged 18 to 59, and flu/COVID combination vaccine CAMBRIDGE, MA / ACCESS Newswire / February 14, 2025 / …

Moderna Gears Up For Q4 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts

Moderna, Inc. MRNA will release its fourth-quarter financial results, before the opening bell, on Friday, Feb. 14, 2025.

Will These 5 Biotech Bigwig Stocks Surpass Q4 Earnings Forecast?

We focus on biotech stocks like VRTX, GILD, BIIB, ALNY and MRNA, which are scheduled to report this week.